Biotron Ltd., of Sydney, received a notice of allowance for U.S. Patent application 11/922,281, “Antiviral Compounds and Methods,” for the composition and methods of treatment with its antiviral compound BIT225. BIT225 is in a phase II trial in HCV genotype 3 patients.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter